-
1.发明授权Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules 有权衍生自与HLA-A2分子复合的法师肿瘤排斥抗原前体的分离的肽公开(公告)号：US06682731B1
公开(公告)日：2004-01-27
申请号：US09533499
申请日：2000-03-23
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre Van Der Bruggen , Pierre Coulie , Thomas Gajewski , Cornelis J. M. Melief , Marjan J. W. Visseren , Martin W. Kast
IPC分类号： A61K4500
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K14/4748
摘要： Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
摘要翻译： 可以使用SEQ ID NO：12和HLA-A2的复合物来产生CTL。 可补充IL-6和IL-12。
-
公开(公告)号：US5585461A
公开(公告)日：1996-12-17
申请号：US217186
申请日：1994-03-24
CPC分类号： C07K14/4748 , A61K38/00 , Y10S530/828 , Y10S530/865
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
-
3.发明授权Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof 失效分离，衍生自与HLA-A2分子复合的MAGE肿瘤排斥抗原前体的肽及其用途
公开(公告)号：US5851523A
公开(公告)日：1998-12-22
申请号：US290381
申请日：1994-08-15
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
IPC分类号： G01N33/574 , A61K35/14 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/04 , C07K7/06 , C07K14/47 , C07K14/54 , C07K14/82 , C07K16/30 , C12N5/06 , C12N15/02 , C12P21/08 , A61K39/385
CPC分类号： C07K14/4748 , A61K38/00
摘要： Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译： 已经鉴定了源自MAGE肿瘤排斥前体的肿瘤排斥抗原。 这些“TRAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。 肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。
-
4.发明授权Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof 失效与HLA-A2分子复合的分离的MAGE-3衍生的肽及其用途
公开(公告)号：US5591430A
公开(公告)日：1997-01-07
申请号：US261160
申请日：1994-06-17
申请人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
发明人： Alan Townsend , Judy Bastin , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Thomas Gajewski
CPC分类号： C07K14/4748 , A61K38/00 , Y10S530/828 , Y10S530/865
摘要： Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
摘要翻译： 已经鉴定了源于肿瘤排斥前体MAGE-3的肿瘤排斥抗原。 这些“TRAS”与MHC-I类分子HLA-A2结合，并且所得复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。 肽和复合物可以用于诊断，治疗和用作产生抗体的免疫原，或用作产生溶细胞T细胞克隆的靶标。
-
5.发明授权Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens 失效通过使用BAGE肿瘤排斥抗原前体或肿瘤排斥抗原治疗受试者的方法公开(公告)号：US06638512B1
公开(公告)日：2003-10-28
申请号：US09382497
申请日：1999-08-25
申请人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
发明人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
IPC分类号： A61K3900
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/70539
摘要： A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一系列肿瘤排斥抗原前体和编码它们的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
6.发明授权Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof 失效编码与MHC分子HLA-Cw * 1601形成复合物的肽的分离的核酸分子及其用途公开(公告)号：US06465184B1
公开(公告)日：2002-10-15
申请号：US09435524
申请日：1999-11-08
申请人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
发明人： Pascale Bo{haeck over (e)}l , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
IPC分类号： C12Q168
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/70539
摘要： A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一系列肿瘤排斥抗原前体和编码它们的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
7.发明授权
公开(公告)号：US5977300A
公开(公告)日：1999-11-02
申请号：US531864
申请日：1995-09-21
IPC分类号： G01N33/50 , A61K31/00 , A61K35/14 , A61K38/00 , A61K39/00 , A61P35/00 , C07H21/04 , C07K7/06 , C07K14/47 , C07K14/705 , C07K14/74 , C12N1/21 , C12N5/02 , C12N5/06 , C12N5/08 , C12N5/10 , C12N15/09 , C12P21/02 , C12Q1/68 , C12R1/91 , G01N33/569 , A61K38/08
CPC分类号： C12Q1/6881 , C07K14/4748 , C07K14/70539 , C12Q1/6886 , G01N33/56977 , A61K39/00 , C12Q2600/112
摘要： Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
摘要翻译： 描述了由HLA-B44分子呈递的肿瘤排斥抗原。 这些肽可用于诊断和治疗方法。 肿瘤排斥抗原不是源自酪氨酸酶，酪氨酸酶先前被鉴定为被HLA-B44呈递的抗原加工的肿瘤排斥抗原前体。
-
8.发明授权Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors 失效分离的编码BAGE肿瘤排斥抗原前体的核酸分子
公开(公告)号：US5571711A
公开(公告)日：1996-11-05
申请号：US79110
申请日：1993-06-17
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07H21/02 , C07H21/04 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/74 , C12N1/21 , C12N5/10 , C12N15/12 , C12P21/02 , C12R1/91 , C12P19/34 , C12N1/15 , C12N1/19 , C12N5/00 , C12N15/00
CPC分类号： C07K14/4748 , C07K14/70539 , A61K38/00
摘要： A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一种新的肿瘤排斥抗原前体家族及其编码的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
公开(公告)号：US06171806B2
公开(公告)日：2001-01-09
申请号：US09266294
申请日：1999-03-11
IPC分类号： G01N33574
CPC分类号： C12Q1/6881 , A61K39/00 , C07K14/4748 , C07K14/70539 , C12Q1/6886 , C12Q2600/112 , G01N33/56977
摘要： Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
摘要翻译： 描述了由HLA-B44分子呈递的肿瘤排斥抗原。 这些肽可用于诊断和治疗方法。 肿瘤排斥抗原不是源自酪氨酸酶，酪氨酸酶先前被鉴定为被HLA-B44呈递的抗原加工的肿瘤排斥抗原前体。
-
10.发明授权Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules 失效确定肿瘤排斥抗原与HLA-Cw * 1601分子复合物的方法
公开(公告)号：US6110694A
公开(公告)日：2000-08-29
申请号：US38328
申请日：1998-03-11
申请人： Pascale Boel , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
发明人： Pascale Boel , Claude Wildmann , Thierry Boon-Falleur , Pierre van der Bruggen , Pierre Coulie , Jean-Christophe Renauld
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07H21/02 , C07H21/04 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/74 , C12N1/21 , C12N5/10 , C12N15/12 , C12P21/02 , C12R1/91 , G01N33/574
CPC分类号： C07K14/4748 , C07K14/70539 , A61K38/00
摘要： A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要翻译： 公开了一系列肿瘤排斥抗原前体和编码它们的核酸分子。 这些肿瘤排斥抗原前体被称为BAGE肿瘤排斥抗原前体，编码它们的核酸分子被称为BAGE编码分子。 描述了编码序列和肿瘤排斥抗原前体分子的各种诊断和治疗用途。
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.032 秒)
